Characterizing Vericiguat Treatment in Heart Failure: A Multicenter Real-World Study in China
In this multicenter, real-world study of vericiguat in Anhui Province, only 44.9% of vericiguat users met the inclusion criteria for the VICTORIA trial. This suggests that vericiguat is being applied more broadly by physicians to treat HF in real clinical settings.
Authors
- Guangchuan Wang (ORCID: https://orcid.org/0000-0001-5315-1599)
- Xueping Wei (ORCID: https://orcid.org/0000-0002-7363-0973)
- Lingxin Pan
- Xuejun Xiang
- Kangyu Chen (ORCID: https://orcid.org/0000-0002-7095-6767)
- Changlin Ju (ORCID: https://orcid.org/0000-0001-6035-6154)
- Zhiquan Liu (ORCID: https://orcid.org/0000-0003-4917-7686)
- Qi Wang (ORCID: https://orcid.org/0000-0002-2186-8496)
- Zhiwei Xu (ORCID: https://orcid.org/0000-0002-0401-8481)
- Ji Yan (ORCID: https://orcid.org/0000-0002-2558-7210)
- Jun Qian (ORCID: https://orcid.org/0000-0002-7324-7624)
- Guohong Wu
- Jiecheng Peng
- Jingjing Li (ORCID: https://orcid.org/0009-0001-9385-0535)
Institutions
- University of Science and Technology of China (CN)
- Huaibei Normal University (CN)
- Bengbu Medical College (CN)
- Anhui Medical University (CN)
- The People's Hospital Tongling (CN)
- Anhui Provincial Hospital (CN)
- Anqing City Hospital (CN)
- First Affiliated Hospital of Wannan Medical College (CN)
- Anhui University of Technology (CN)
Publication Details
- Journal
- Reviews in Cardiovascular Medicine
- Published
- 2024-11-29
- DOI
- https://doi.org/10.31083/j.rcm2512427
- Citations
- 3
- Primary Topic
- Heart Failure Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.21